spironolactone has been researched along with Aging in 34 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure." | 9.41 | The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. ( Ahmed, FZ; Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Collier, TJ; Cosmi, F; Cuthbert, J; Diez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Grojean, S; Hazebroek, M; Heymans, S; Khan, J; Latini, R; Mamas, MA; Mariottoni, B; McDonald, K; Mujaj, B; Pellicori, P; Petutschnigg, J; Pieske, B; Pizard, A; Rossignol, P; Rouet, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2021) |
| " The Heart OMics in AGing (HOMAGE) trial aims to investigate the effects of spironolactone on serum markers of collagen metabolism and on cardiovascular structure and function in people at risk of developing HF and potential interactions with a marker of fibrogenic activity, galectin-3." | 9.34 | Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO ( Ahmed, FZ; Brunner-La Rocca, HP; Clark, AL; Cleland, JGF; Collier, T; Cosmi, F; Cuthbert, JJ; Ferreira, JP; Girerd, N; González, A; Heymans, S; Latini, R; Mariottoni, B; Mujaj, B; Pellicori, P; Petutschnigg, J; Rossignol, P; Staessen, JA; Verdonschot, J; Zannad, F, 2020) |
| "To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure." | 5.41 | The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. ( Ahmed, FZ; Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Collier, TJ; Cosmi, F; Cuthbert, J; Diez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Grojean, S; Hazebroek, M; Heymans, S; Khan, J; Latini, R; Mamas, MA; Mariottoni, B; McDonald, K; Mujaj, B; Pellicori, P; Petutschnigg, J; Pieske, B; Pizard, A; Rossignol, P; Rouet, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2021) |
| " The Heart OMics in AGing (HOMAGE) trial aims to investigate the effects of spironolactone on serum markers of collagen metabolism and on cardiovascular structure and function in people at risk of developing HF and potential interactions with a marker of fibrogenic activity, galectin-3." | 5.34 | Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO ( Ahmed, FZ; Brunner-La Rocca, HP; Clark, AL; Cleland, JGF; Collier, T; Cosmi, F; Cuthbert, JJ; Ferreira, JP; Girerd, N; González, A; Heymans, S; Latini, R; Mariottoni, B; Mujaj, B; Pellicori, P; Petutschnigg, J; Rossignol, P; Staessen, JA; Verdonschot, J; Zannad, F, 2020) |
| "We report four cases of hyperkalemia induced by the association of spironolactone with ACE inhibitor in geriatric patients." | 3.70 | Elderly heart failure patients with drug-induced serious hyperkalemia. ( Swine, CH; Vanpee, D, 2000) |
| "Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart." | 1.36 | Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010) |
| "Spironolactone did not enhance water and electrolyte excretion." | 1.30 | Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. ( Chander, PN; Khanna, K; Rocha, R; Stier, CT; Zuckerman, A, 1998) |
| " On comparison of the pharmacokinetic parameters with the respective values of a control group of younger healthy female subjects, the serum concentrations in the elderly patients were found to be twice as high." | 1.27 | The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone. ( Abshagen, U; Horn, HJ; Mühlberg, W; Platt, D; Schmitt-Rüth, R; Vollmar, J, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (41.18) | 18.7374 |
| 1990's | 6 (17.65) | 18.2507 |
| 2000's | 4 (11.76) | 29.6817 |
| 2010's | 7 (20.59) | 24.3611 |
| 2020's | 3 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Pellicori, P | 2 |
| Ferreira, JP | 2 |
| Mariottoni, B | 2 |
| Brunner-La Rocca, HP | 1 |
| Ahmed, FZ | 2 |
| Verdonschot, J | 1 |
| Collier, T | 1 |
| Cuthbert, JJ | 1 |
| Petutschnigg, J | 2 |
| Mujaj, B | 2 |
| Girerd, N | 2 |
| González, A | 2 |
| Clark, AL | 2 |
| Cosmi, F | 2 |
| Staessen, JA | 2 |
| Heymans, S | 2 |
| Latini, R | 2 |
| Rossignol, P | 2 |
| Zannad, F | 2 |
| Cleland, JGF | 2 |
| Cuthbert, J | 1 |
| Verdonschot, JAJ | 1 |
| Brunner La Rocca, HP | 1 |
| Mamas, MA | 1 |
| Edelmann, F | 1 |
| Pieske, B | 1 |
| Khan, J | 1 |
| McDonald, K | 1 |
| Rouet, P | 1 |
| Diez, J | 1 |
| Hazebroek, M | 1 |
| Grojean, S | 1 |
| Pizard, A | 1 |
| Collier, TJ | 1 |
| Pitt, B | 1 |
| Byrd, JB | 1 |
| Hwang, MH | 2 |
| Yoo, JK | 2 |
| Luttrell, M | 2 |
| Kim, HK | 2 |
| Meade, TH | 2 |
| English, M | 2 |
| Nichols, WW | 1 |
| Christou, DD | 2 |
| Demiralay, C | 1 |
| Agorastos, A | 1 |
| Steiger, A | 1 |
| Wiedemann, K | 1 |
| Paar, M | 1 |
| Pavenstädt, H | 1 |
| Kusche-Vihrog, K | 1 |
| Drüppel, V | 1 |
| Oberleithner, H | 1 |
| Kliche, K | 1 |
| Talcott, S | 1 |
| Jaffe, IZ | 1 |
| Stein, M | 1 |
| Boulaksil, M | 1 |
| Jansen, JA | 1 |
| Herold, E | 1 |
| Noorman, M | 1 |
| Joles, JA | 1 |
| van Veen, TA | 1 |
| Houtman, MJ | 1 |
| Engelen, MA | 1 |
| Hauer, RN | 1 |
| de Bakker, JM | 1 |
| van Rijen, HV | 1 |
| Yau, JL | 1 |
| Noble, J | 1 |
| Seckl, JR | 1 |
| Burton, LA | 1 |
| McMurdo, ME | 1 |
| Struthers, AD | 1 |
| McMurray, JJ | 1 |
| O'Meara, E | 1 |
| Giordano, R | 1 |
| Bo, M | 1 |
| Pellegrino, M | 1 |
| Vezzari, M | 1 |
| Baldi, M | 1 |
| Picu, A | 1 |
| Balbo, M | 1 |
| Bonelli, L | 1 |
| Migliaretti, G | 1 |
| Ghigo, E | 1 |
| Arvat, E | 1 |
| Hwang, HS | 1 |
| Cirrincione, G | 1 |
| Thomas, DP | 1 |
| McCormick, RJ | 1 |
| Boluyt, MO | 1 |
| Platt, D | 2 |
| Abshagen, U | 1 |
| Mühlberg, W | 1 |
| Horn, HJ | 1 |
| Schmitt-Rüth, R | 1 |
| Vollmar, J | 1 |
| Johnson, MH | 1 |
| Hyneck, ML | 1 |
| Fujimura, A | 1 |
| Sunaga, K | 1 |
| Ebihara, A | 1 |
| Rocha, R | 1 |
| Chander, PN | 1 |
| Khanna, K | 1 |
| Zuckerman, A | 1 |
| Stier, CT | 1 |
| Kubisch, HM | 1 |
| Mathialagan, S | 1 |
| Gómez-Sánchez, EP | 1 |
| Zemanová, Z | 1 |
| Pácha, J | 2 |
| Vanpee, D | 1 |
| Swine, CH | 1 |
| Svechnikova, NV | 1 |
| Bekker, VI | 1 |
| Magdich, LV | 1 |
| Chowanetz, W | 1 |
| Rückert, KH | 1 |
| Juchems, R | 1 |
| Gross-Fengels, F | 1 |
| Garg, BD | 1 |
| Kourounakis, P | 1 |
| Tuchweber, B | 1 |
| Kitani, K | 1 |
| Kanai, S | 1 |
| Miura, R | 1 |
| Morita, Y | 1 |
| Kasahara, M | 1 |
| Sato, N | 1 |
| Kamada, T | 1 |
| Suematsu, T | 1 |
| Abe, H | 1 |
| Furuyama, F | 1 |
| Hagihara, B | 1 |
| Svitasheva, NG | 1 |
| Kalish, EE | 1 |
| Logvinenko, NS | 2 |
| Solenov, EI | 2 |
| Khlebodarova, TM | 1 |
| Ivanova, LN | 1 |
| Broude, NE | 1 |
| Monastyrskaia, GS | 1 |
| Caine, M | 1 |
| Popp, M | 1 |
| Capek, K | 1 |
| Guibert, EE | 1 |
| Rodriguez, JV | 1 |
| Garcia, G | 1 |
| Rodriguez Garay, EA | 1 |
| Massie, B | 1 |
| Klaassen, CD | 1 |
| Dunihue, FW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) HOMAGE Programme Heart OMics in AGing "[NCT02556450] | Phase 2 | 528 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for spironolactone and Aging
| Article | Year |
|---|---|
Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?
Topics: Aged; Aged, 80 and over; Aging; Humans; Mineralocorticoid Receptor Antagonists; Mobility Limitation; | 2011 |
7 trials available for spironolactone and Aging
| Article | Year |
|---|---|
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO
Topics: Aged; Aging; Biomarkers; Diabetes Mellitus, Type 2; Female; Fibrosis; Heart Failure; Humans; Male; N | 2020 |
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Topics: Aged; Aging; Biomarkers; Female; Fibrosis; Heart Failure; Humans; Male; Peptide Fragments; Procollag | 2021 |
Role of mineralocorticoid receptors in arterial stiffness in human aging.
Topics: Aged; Aging; Blood Pressure; Cross-Over Studies; Double-Blind Method; Eplerenone; Female; Humans; Ma | 2013 |
Sleep EEG effects of anti-gluco- and anti-mineralocorticoids in old-aged men: pilot study.
Topics: Aged; Aged, 80 and over; Aging; Electroencephalography; Humans; Male; Mifepristone; Mineralocorticoi | 2014 |
Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults.
Topics: Aged; Aging; Biomarkers; Blood Proteins; Brachial Artery; Cross-Over Studies; Double-Blind Method; E | 2016 |
Hypothalamus-pituitary-adrenal hyperactivity in human aging is partially refractory to stimulation by mineralocorticoid receptor blockade.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Aging; Canrenoic Acid; Circadian Rhythm; Dehydroepiandrost | 2005 |
[Effect of aldactone on the mineralocorticoid function of the adrenal cortex and the sodium and potassium content in the blood of middle-aged and elderly persons].
Topics: Adrenal Cortex; Adult; Aged; Aging; Aldosterone; Clinical Trials as Topic; Drug Evaluation; Erythroc | 1978 |
26 other studies available for spironolactone and Aging
| Article | Year |
|---|---|
Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.
Topics: Aging; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; ras Proteins; Spiron | 2021 |
Endothelial sodium channels trigger endothelial salt sensitivity with aging.
Topics: Aging; Amiloride; Animals; Aorta; Endothelium, Vascular; Epithelial Sodium Channels; Mice; Sodium Ch | 2014 |
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr | 2010 |
11beta-hydroxysteroid dehydrogenase type 1 deficiency prevents memory deficits with aging by switching from glucocorticoid receptor to mineralocorticoid receptor-mediated cognitive control.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Aging; Analysis of Variance; Animals; Cognition; Cortic | 2011 |
Treatment of heart failure with spironolactone--trial and tribulations.
Topics: Adrenergic beta-Antagonists; Aging; Aldosterone; Drug Therapy, Combination; Glomerular Filtration Ra | 2004 |
Aldosterone antagonism fails to attenuate age-associated left ventricular fibrosis.
Topics: Aging; Aldosterone; Animals; Atrial Natriuretic Factor; Collagen; Collagen Type III; Female; Fibrosi | 2007 |
The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
Topics: Aged; Aging; Blood Proteins; Canrenone; Chromatography, High Pressure Liquid; Disease; Erythrocyte C | 1984 |
Comparison of methods for estimating digoxin dosing regimens: further analysis.
Topics: Adult; Aged; Aging; Creatinine; Digoxin; Female; Humans; Kidney; Male; Middle Aged; Spironolactone | 1981 |
Administration time-dependent change in the effect of spironolactone in aged rats.
Topics: Aging; Animals; Drug Administration Schedule; Male; Rats; Rats, Wistar; Sodium; Spironolactone | 1994 |
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
Topics: Aging; Animals; Body Weight; Brain; Cerebrovascular Disorders; Delayed-Action Preparations; Diuresis | 1998 |
Modulation of blood pressure in the Dahl SS/jr rat by embryo transfer.
Topics: Adult; Aging; Animals; Blood Pressure; Cerebral Ventricles; Embryo Transfer; Female; Genotype; Human | 1998 |
Localization of Na,K-ATPase activity in developing rat distal colon: role of corticosteroids.
Topics: 4-Nitrophenylphosphatase; Adrenal Cortex Hormones; Adrenalectomy; Aging; Aldosterone; Animals; Colon | 1998 |
Elderly heart failure patients with drug-induced serious hyperkalemia.
Topics: Aged; Aging; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Dose-Response Relationship, Drug; | 2000 |
[Therapy of the bronchitic syndrome in the elderly].
Topics: Aged; Aging; Anti-Bacterial Agents; Breathing Exercises; Bronchitis; Chronic Disease; Cromolyn Sodiu | 1977 |
Influence of age and spironolactone on lysosomal enzyme activities, DNA and protein content of the rat liver after partial hepatectomy.
Topics: Acetylglucosaminidase; Aging; Animals; Cathepsins; DNA; Female; Glucuronidase; Hepatectomy; Liver; L | 1979 |
Fine structural changes in the liver of young and old rats as influenced by microsomal enzyme inducers.
Topics: Aging; Animals; Dexamethasone; Endoplasmic Reticulum; Enzyme Induction; Liver; Male; Microsomes, Liv | 1979 |
The effect of ageing on the biliary excretion of ouabain in the rat.
Topics: Aging; Animals; Bile; Male; Ouabain; Rats; Spironolactone; Time Factors | 1978 |
Cadmium toxicity and liver mitochondria. II. Protective effect of hepatic soluble fraction against cadmium-induced mitochondrial dysfunction.
Topics: Adenosine Diphosphate; Aging; Animals; Cadmium; Cytochromes; Cytosol; Liver; Male; Mitochondria, Liv | 1978 |
[The age-related characteristics of the hormonal regulation of Na+, K(+)-ATPase activity in the kidney cortex of rats].
Topics: Adrenalectomy; Aging; Aldosterone; Animals; Kidney Cortex; Kidney Tubules, Collecting; Kidney Tubule | 1992 |
[The hormonal regulation of mRNA Na,K-ATPase expression in rat kidneys in postnatal ontogeny].
Topics: Adrenalectomy; Aging; Aldosterone; Animals; Dexamethasone; Enzyme Induction; Gene Expression Regulat | 1991 |
Medical management of prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aging; Bromocriptine; Cyproterone; Humans; Male; Phenoxybenzamin | 1986 |
Corticosteroid regulation of Na+ and K+ transport in the rat distal colon during postnatal development.
Topics: Adrenal Cortex Hormones; Adrenalectomy; Aging; Aldosterone; Amiloride; Animals; Animals, Suckling; C | 1988 |
Biochemical and morphometric analysis of the effect of spironolactone on the livers from immature and adult rats.
Topics: Aging; Animals; Body Weight; Cell Nucleus; Cytoplasm; Liver; Macromolecular Substances; Male; Organ | 1987 |
Updated diagnosis and management of congestive heart failure.
Topics: Aged; Aging; Angiography; Diagnosis, Differential; Diuretics; Echocardiography; Female; Heart Failur | 1986 |
Stimulation of the development of the hepatic excretory mechanism for ouabain in newborn rats with microsomal enzyme inducers.
Topics: Aging; Animals; Animals, Newborn; Bile; Enzyme Induction; Liver; Methylcholanthrene; Microsomes, Liv | 1974 |
Reversal of the reduced juxtaglomerular cell granularity (GCI) in old rats.
Topics: Adrenal Insufficiency; Adrenalectomy; Aging; Animals; Cortisone; Female; Juxtaglomerular Apparatus; | 1971 |